InvestorsHub Logo
Followers 9
Posts 169
Boards Moderated 0
Alias Born 03/09/2020

Re: None

Wednesday, 04/29/2020 6:08:22 PM

Wednesday, April 29, 2020 6:08:22 PM

Post# of 233276
In case you guys missed this....NEJM letter to the editor from Montefiore Medical Center.

NEJM study

"Six severely ill patients received the CCR5 inhibitor leronlimab (PRO 140, CytoDyn) on a compassionate-use basis, and 2 received the interleukin-6 receptor antagonist tocilizumab. Interleukin-6 levels were very elevated (range, 83 to 8175 pg per milliliter) when leronlimab was initiated (on day 0) in the 5 patients with elevated interleukin-6 levels; these levels decreased markedly 3 days later (range, 37 to 2022 pg per milliliter) (see Table S2 in the Supplementary Appendix). However, only the 1 patient who had the lowest interleukin-6 level (at 83 pg per milliliter) remained in stable condition without intubation."

“The score never interested me, only the game.”
Mae West

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News